» Articles » PMID: 36683740

Superstable Homogeneous Lipiodol-ICG Formulation: Initial Feasibility and First-in-human Clinical Application for Ruptured Hepatocellular Carcinoma

Overview
Journal Regen Biomater
Date 2023 Jan 23
PMID 36683740
Authors
Affiliations
Soon will be listed here.
Abstract

The most common treatment of spontaneous tumor rupture hemorrhage (STRH) is transcatheter arterial embolization (TAE) followed by liver resection, and surgical navigation using near-infrared fluorescence is effective method for detecting hidden lesions and ill-defined tumor boundaries. However, due to the blockage of the tumor-supplying artery after effective TAE treatment, it is difficult to deliver sufficient fluorescent probes to the tumor region. In this study, we report on the successful application of superstable homogeneous intermixed formulation technology (SHIFT) in precise conversion hepatectomy for ruptured hepatocellular carcinoma (HCC). A homogeneous lipiodol-ICG formulation obtained by SHIFT (SHIFT-ICG) was developed for clinical practice for STRH. A ruptured HCC patient received the combined protocol for embolization and fluorescence surgical navigation and exhibited excellent hemostatic effect. Lipiodol and ICG were both effectively deposited in the primary lesion, including a small metastatic lesion. In follow-up laparoscopic hepatectomy, SHIFT-ICG could clearly and precisely image the full tumor regions and boundaries in real time, and even indistinguishable satellite lesions still expressed a remarkable fluorescence intensity. In conclusion, the simple and green SHIFT-ICG formulation can be effectively used in emergency embolization hemostasis and later precise fluorescence navigation hepatectomy in patients with ruptured HCC bleeding and has high clinical application value.

Citing Articles

Fluorescence-guided Surgery for Hepatocellular Carcinoma: From Clinical Practice to Laboratories.

Xiao T, Chen D, Peng L, Li Z, Pan W, Dong Y J Clin Transl Hepatol. 2025; 13(3):216-232.

PMID: 40078203 PMC: 11894393. DOI: 10.14218/JCTH.2024.00375.


Supercritical Fluids: An Innovative Strategy for Drug Development.

Liu H, Liang X, Peng Y, Liu G, Cheng H Bioengineering (Basel). 2024; 11(8).

PMID: 39199746 PMC: 11351119. DOI: 10.3390/bioengineering11080788.

References
1.
Anderson J . Future challenges in the in vitro and in vivo evaluation of biomaterial biocompatibility. Regen Biomater. 2016; 3(2):73-7. PMC: 4817327. DOI: 10.1093/rb/rbw001. View

2.
He P, Xiong Y, Ye J, Chen B, Cheng H, Liu H . A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection. J Nanobiotechnology. 2022; 20(1):250. PMC: 9164554. DOI: 10.1186/s12951-022-01467-w. View

3.
He P, Huang T, Fang C, Su S, Tian J, Xia X . Identification of extrahepatic metastasis of hepatocellular carcinoma using indocyanine green fluorescence imaging. Photodiagnosis Photodyn Ther. 2019; 25:417-420. DOI: 10.1016/j.pdpdt.2019.01.031. View

4.
He P, Ren E, Chen B, Chen H, Cheng H, Gao X . A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma. Theranostics. 2022; 12(4):1769-1782. PMC: 8825598. DOI: 10.7150/thno.68456. View

5.
McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View